Company Description
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide.
The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Its hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process.
Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012.
Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
| Country | United States |
| Founded | 1994 |
| IPO Date | Jan 27, 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 244 |
| CEO | Mark Strobeck |
Contact Details
Address: 30142 South Wixom road Wixom, Michigan 48393 United States | |
| Phone | 248 960 9009 |
| Website | rockwellmed.com |
Stock Details
| Ticker Symbol | RMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001041024 |
| CUSIP Number | 774374300 |
| ISIN Number | US7743743004 |
| Employer ID | 38-3317208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Strobeck Ph.D. | President, Chief Executive Officer and Director |
| Jesse Neri | Senior Vice President and Chief Financial Officer |
| Megan C. Timmins | Executive Vice President, Chief Legal Officer and Secretary |
| Nicholas Fanslau | Controller and Principal Accounting Officer |
| Timothy T. Chole | Senior Vice President and Chief Commercial Officer |
| Heather H. Hunter | Senior Vice President and Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 2, 2025 | 144 | Filing |